DRTECH Q1 2026 Sales Up 25%, Operating Loss Narrows; New Product Launches Drive Growth

Consolidated sales KRW 31.8bn (up 25.5% YoY from 25.4bn), operating loss KRW 0.6bn (improved from -3.5bn)
Net loss KRW 0.9bn (vs -4.4bn), EPS -11 won (vs -61 won) – profitability trend improving
New product: March launch of 3D tomosynthesis-guided biopsy system 'AIDIA LUXE TRUMETRIC' (MFDS approval)
Expanded supply agreement for 'EXPEED series' dynamic detector with European dental X-ray company A
R&D spending KRW 3.7bn (12% of sales), 3 new patents registered (C-arm related in US and Europe)
Financial position: Total assets KRW 205.1bn, liabilities KRW 128.9bn, equity KRW 76.2bn; total borrowings & CBs KRW 48.8bn (short-term 19.7bn, long-term 7.3bn, CBs 40.1bn)
Retained earnings deficit -44.8bn, allowance for doubtful accounts KRW 4.8bn (up from 2.8bn) – increased credit risk
Shareholder returns: No share buyback/cancellation, no dividend paid (preferred stock 0.1% dividend rate but unpaid)
7 consolidated subsidiaries; major subsidiaries DRTECH North America, Europe, China contributed to sales growth